CD274 and cancer: The correlation of clinical benefit and expression of PD-L1 using archival tissues needs further validation, particularly in recurrent women’s cancers given preanalytical variabilities (e.g., different IHC techniques, score systems, different antibodies [23, 24]) and possible dynamic changes of PD-L1 expression affected by prior therapies [25].